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and cognitive eVects
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Abstract
Objective—To determine the eYcacy, tol-
erability, and impact on quality of life and
cognitive functioning of anticonvulsant
prophylaxis with phenytoin or sodium
valproate in patients after craniotomy.
Methods—A prospective, stratified, ran-
domised, double blind single centre clini-
cal trial was performed, comparing two
groups of 50 patients each, who underwent
craniotomy for diVerent pathological con-
ditions and who were treated for 1 year
after surgery with either 300 mg
phenytoin/day or 1500 mg sodium
valproate/day. During the study period
patients were seen in the outpatient clinic
at 1.5, 3, 6, and 12 months, when medical
history, adverse events, and drug plasma
concentrations were evaluated. Neuro-
psychological functioning and quality of
life were assessed on the last three visits.
In cases of a seizure an EEG was per-
formed, drug plasma concentration as-
sessed, and medication subsequently
increased.
Results—Of the 100 included patients 14
(seven in each group) experienced one or
more postoperative seizures. Severity of
the seizures was comparable in the two
groups. In all patients, drug plasma
concentrations were in the low or sub-
therapeutic ranges at the time of the first
postoperative seizure. Five patients in the
phenytoin group and two in the valproate
group had to stop their treatment due to
drug related adverse events. Sixty patients
completed the 12 month period. Analysis
of neuropsychological and quality of life
data showed no significant diVerences.
Conclusion—For eYcacy, tolerability, im-
pact on cognitive functioning, and quality
of life, no major diVerences were found
between phenytoin and valproate prophy-
laxis. Valproate is an alternative for anti-
convulsant prophylaxis in patients after
craniotomy.
(J Neurol Neurosurg Psychiatry 1999;67:474–480)
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Neurosurgical procedures invading the anterior
or middle cranial fossa carry the risk of post-
operative epilepsy.1 2 The incidence of epilepsy
primarily depends on the underlying pathology;
the overall incidence is estimated to be 17%.3
Some neurosurgical diseases are related to a
relatively high incidence of postoperative
seizures—for example, cerebral abcess and head
trauma with intracerebral haematoma.4–7 Other
specific high risk patient categories are: aneurys-
mal subarachnoid haemorrhage,8 9 arterio-
venous malformation,10 11 meningioma,12–14 and
glioma.15 16 In brain tumours the incidence is
roughly inversely related to the degree of
malignancy.1 15 16 Another important determi-
nant of postoperative epilepsy is the location of
the lesion: falx and parasagittal meningiomas
have a higher incidence than meningiomas
located elsewhere,9 14 17 and aneurysms of the
middle cerebral artery carry a higher risk of
epilepsy than other aneurysms.18 Other known
factors of influence for postoperative epilepsy
are complications (infection, ischaemia) and the
surgical approach to the lesion.9
The untoward eVects of epilepsy are found
in transient or permanent neurological disabil-
ity and complications in the direct postopera-
tive period.2 19 20 Socioeconomic consequences
of epilepsy can be severe—for example, occur-
rence of a seizure may result in the loss of
a person’s driving licence,21 underscoring
the importance of preventing seizures when
possible.
As prophylaxis after a craniotomy, anticon-
vulsant drugs should ideally be easy to use,
provide adequate control, and generate no
major side eVects. Especially in postoperative
patients sedative eVects are unwanted because
of interference with adequate diagnosis of
postoperative complications such as haemor-
rhage. Intravenous preparations are necessary
during recovery from anaesthesia. In postcrani-
otomy prophylaxis the most widely used drug
today is phenytoin. Until now, reports on the
use of sodium valproate for this indication are
limited. Price found a control rate of nearly
90% in 70 neurosurgical patients who previ-
ously had at least five seizures/month.22 Most
required daily doses of less than 2 g/day of
sodium valproate; three patients had to stop
treatment due to drug intolerance.
Treatment of epilepsy with sodium valproate
in therapeutic doses is thought to produce
relatively few cognitive side eVects.23 24 Al-
though its superiority in this respect over older
drugs such as phenobarbital is well established,
the advantage of valproate over phenytoin is
less clear. Results of direct comparisons on
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cognitive function between the last two have
been equivocal or slightly in favour of
valproate.25–28 Possibly a diVerential eVect is
clearer in patients with lesions, in whom
anticonvulsant medication seems to have more
impact on cognition than in patients with idio-
pathic epilepsy.29 However, this may not be easy
to assess, as the study of such patients
introduces numerous potential confounding
factors, such as lesion size and rate of recovery.
Nevertheless, the presence of brain damage
may interact with type of medication to cause
observable diVerences with respect to neuro-
psychological test performance or subjective
wellbeing.
In view of this possibility it was considered
worthwhile to compare cognitive function in
neurosurgical patients who were prophylacti-
cally treated with either valproate or phenytoin
(intravenously and orally), using neuropsycho-
logical tests focused on attention, memory, and
speed of information processing as well as per-
ceived quality of life. Our aim was to compare
the eYcacy and tolerability of sodium valproate
with phenytoin.
Patients and methods
DESIGN
A single centre, stratified, randomised, double
blind, comparative clinical trial was performed.
The procedures followed were approved by the
institutional ethics committee, and were in
accordance with the Helsinki Declaration of
1975, as revised in 1983. Randomisation
started in August 1993 and was stopped after
reaching the preset inclusion of 100
patients—50 patients in each group—in Au-
gust 1995. Patients were stratified depending
on the type of their intracranial pathology:
brain tumour, trauma, or vascular lesions.
Random allocation was carried out with sealed
envelopes for each stratum, each patient
receiving a separate treatment number deter-
mining whether the patient was treated with
phenytoin or valproate. Sanofi Winthrop Re-
cherche, Montpellier, France provided all pre-
coded packaged material.
CRITERIA FOR INCLUSION
Patients could be included if they would
undergo supratentorial surgery for one of the
above mentioned pathological conditions, were
aged between 18 and 80 years, and had given
written informed consent. Exclusion criteria
were: a life expectancy of less than 6 months,
preoperative use of anticonvulsant drugs for
more than 3 months, a history of epileptic sei-
zures apart from seizures caused by the
presenting disease (this was the case in 23
patients, most of whom had a glioma), chronic
use of psychopharmaceuticals, alcohol or drug
misuse, severe psychiatric illness, and partici-
pation in an experimental drug trial. The
demographic data of the included patients are
presented in table 1. In view of the few trauma
cases, the strata were collapsed to two catego-
ries (tumour v other).
DRUG TREATMENT
Intravenous administration of 100 mg pheny-
toin thrice daily or 500 mg valproate thrice
daily was started immediately postoperatively
in the recovery room. We did not use loading
doses. As soon as possible, patients switched to
the same regimen in oral formulation of
phenytoin or valproate (Depakine chrono®).
In selected cases of critically ill patients with a
long stay in the intensive care unit, medication
was administered as syrup via a nasogastric
tube. No other maintenance anticonvulsant
medication, including barbiturates, hypnotics,
and benzodiazepines, was acceptable during
the study. Otherwise, the patient was with-
drawn from the study and considered a
treatment failure.
In cases of adverse events, intoxication or
toxic drug plasma concentrations (>200 mg/l
valproate and 50 mg/l phenytoin) the medi-
cation regimen was adjusted at the judgement
of the unblinded investigator (DGAK), who
was not otherwise involved in the data
collection. Subsequent control plasma concen-
trations were taken. In case of a seizure a
detailed description of the event was obtained
to classify it according to the ILAE inter-
national classification and elaborate its severity
according to the national hospital seizure
severity score NHS3.30 31 If possible, a drug
plasma concentration was taken, an EEG was
performed, and medication was adjusted.
PHARMACOKINETIC CALCULATIONS
Average individual steady state serum concen-
trations were calculated using the population
pharmacokinetic software programme MW/
Pharm with general population models for
phenytoin and valproic acid.32 Models were fit
to the patient data (weight, height, age) and
serum concentration data using Bayesian
regression to obtain the individual pharma-
cokinetic parameters (phenytoin: volume of
distribution and elimination rate constant).
These individualised pharmacokinetic param-
eters were used to calculate individual steady
state serum concentrations.
ASSESSMENTS
During the recovery period, vital signs, adverse
events, and a drug plasma concentration on the
third postoperative day were assessed. Patients
were followed up for 1 year, during which
Table 1 Baseline characteristics of study groups
Parameter Phenytoin Valproate Total
No of cases 50 50 100
Men/women 26 / 24 21 / 29 47 / 53
Mean age/ range (y) 55 / 21–78 51 / 21–77 53 / 21–78
Completed 12 months 29 (27) 31 (28) 60 (55)
Pathology:
Malignant glioma 7 (0) 11 (2) 18 (2)
Low grade glioma 2 (1) 1 (1) 3 (2)
Metastasis 9 (2) 4 (1) 13 (3)
Meningioma 7 (6) 8 (7) 15 (13)
Other tumours* 4 (4) 4 (4) 8 (8)
Traumatic head injury 2 (1) 2 (1) 4 (2)
Chronic subdural haematoma 1 (0) 2 (2) 3 (2)
Intracranial haemorrhage 3 (2) 1 (1) 4 (3)
Aneurysmal SAH 15 (11) 13 (5) 28 (16)
Cavernoma 0 (0) 4 (4) 4 (4)
* Other brain tumors were a pituitary adenoma, neurocytoma, schwannoma, and a haemangio-
blastoma in the phenytoin group, and two colloid cysts, a pitiutary adenoma, and a hamartoma in
the valproate group. SAH=Subarachnoid haemorrhage. The number of patients with complete
cognitive assessment are shown in parentheses..
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period they were controlled by the study coor-
dinator (LFMB) at the outpatient clinic at 1.5,
3, 6, and 12 months for: medical history
including possible seizures and adverse eVects
of the anticonvulsant, physical examination,
Karnofsky performance status, and laboratory
tests including drug plasma concentration. At
3, 6, and 12 months neuropsychological and
quality of life tests were administered.
NEUROPSYCHOLOGICAL TESTS
Neuropsychological tests consisted of two
standard clinical tasks and three computerised
tasks; the last were derived from a battery
designed for the testing of epileptic patients
and have been shown to be useful in the study
of anticonvulsant drugs.33–35
(1) Serial word learning36
The learning of a list of 15 orally presented
words is measured by immediate recall (sum of
5 trials), delayed recall after an interval of 20
minutes, and recognition (yes/no choice in a list
of 30 words).
(2) Categoric word fluency, derived from a Dutch
intelligence test37
The patient is required to name as many
animals and professions as possible, one
minute each.
(3) Simple auditory reaction time
The space bar must be pressed as fast as possi-
ble with the preferred hand in response to an
auditory stimulus. Performance is measured as
the median reaction time in 30 trials.
(4) Binary choice task
The patient must press a left or right key in
response to respectively a green square on the
left side and a red square on the right side of
the screen, appearing in random alternation.
Each response is immediately followed by a
new stimulus. Performance is measured by the
average reaction time in 60 trials.
(5) Visual searching task
A non-verbal design in the centre of the screen
must be matched to one out of 24 surrounding
patterns. Performance is measured by the aver-
age search time in 24 trials.
The Dutch version of the National adult
reading test,38 a measure of vocabulary insensi-
tive to brain dysfunction,39 was administered
on the visit at 3 months to estimate premorbid
intelligence.
QUALITY OF LIFE MEASURES
Emotional status was measured with a short-
ened Dutch version of the profile of mood
states (POMS),40 41 which yields five subscales:
depression, anger, fatigue, vigour, and tension.
Fatigue was additionally assessed with the
more extensive fatigue severity scale (FSS).42
Furthermore, a self developed questionnaire
was administered, previously employed in a
study in patients with low grade glioma,43
referring to perceived dependency in activities
of daily living (six three point items), physical
complaints (seven three point items), cognitive
restrictions (five five point items), sense of
restriction in daily functioning (one five point
item), satisfaction with health (one five point
item), and general wellbeing (one five point
item).
ANALYSIS
At the end of the study, recorded variables for
each individual patient were elaborated and
analysed. Outcome measurements for the
study were: eYcacy as determined by the
occurrence of seizures and their severity score
following the national hospital seizure severity
score, clinical tolerability, cognitive functioning
evaluated by neuropsychological tests, and
quality of life. For eYcacy, seizure severity, and
tolerability, group diVerences were tested with
t tests and non-parametric tests (÷2 or Fisher’s
exact, Mann-Whitney U test) as appropriate.
Neuropsychological and quality of life data
were analysed with repeated measurements
analysis of variance (ANOVA), using polyno-
mial contrasts. Independent variables were
group (phenytoin v valproate) and stratum
(tumour v other). The outcomes considered—
reflecting possible diVerential medication
eVects—were the overall group diVerence
(phenytoin v valproate) and the linear or quad-
ratic group by visit interaction. This analysis
was restricted to 55 patients who could be fully
tested on all three occasions (table 1), which
excluded 11 patients who were tested partially
and 24 who could not be tested at all. Due to a
high mortality, the excluded group contained
most patients with high grade gliomas or meta-
static tumours. A power analysis indicated that,
given the design and group size, the statistical
power to show significance for a diVerence of
0.5 SD at the two tailed 5% level was 0.87.
Significance was accepted at the two tailed 5%
level.
Results
DEMOGRAPHY
No significant diVerences were found in
baseline characteristics (sex, age, pathology,
and history of preoperative seizures) of the
medicine groups, either in the total sample or
in the subgroups with complete neuropsycho-
logical and quality of life data. The estimated
premorbid IQ was distributed equally (pheny-
toin: 101 (SD 14), valproate: 100 (SD 14) in
the last two. Causes of drop out are listed in
table 2. The mortality rate tended to be higher
in tumour patients with phenytoin than in
those with valproate (43% v 18%), but the dif-
ference did not reach significance (÷2=3.04,
p<0.10). In other patients there was a non-
significant opposite tendency (phenytoin 5%
mortality, valproate 23%; p=0.19, Fisher’s
exact test).
EFFICACY
Postoperative seizures occurred in both the
phenytoin group and the valproate group in
seven patients (table 3). The time of occur-
rence of the first seizure is shown in the figure.
In both groups two patients had their first sei-
zure on the day of operation. No diVerence was
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found in time to first seizure between pheny-
toin and valproate users (Mann-Whitney U
test). Between the two groups the severity of
the seizures (according to the NHS-3) showed
no significant diVerence (Mann-Whitney U
test). In patients with multiple seizures, neither
a decrease nor an increase in severity over time
could be found.
SEIZURE ASSOCIATIONS
In nine of the 14 patients who experienced
postoperative seizures, a primary or secondary
brain malignancy was the underlying pathol-
ogy. In four cases (two in each group), a recur-
rent tumour (after 11, 17, 23, and 29 weeks
respectively) was concurrent with seizure pres-
entation. Seizures were associated with a com-
plicated postoperative course in four patients
(two ischaemia, one oedema, one haemor-
rhage). In six of the 14 patients with postopera-
tive seizures the occurrence of seizures was not
related to either perioperative complications or
radiological recurrence.
DRUG PLASMA CONCENTRATIONS AND EFFICACY
Drug plasma concentrations taken after the
first postoperative seizure were below the usual
therapeutic range(<8 mg/l phenytoin, <50 mg/l
valproate) in all seven patients of the phenytoin
group and four out of the seven patients in the
valproate group; in the other three valproate
patients drug concentrations were below 62
mg/l. In the 10 patients whose first seizure
occurred more than 1 day after the operation,
the mean drug plasma concentrations were 5.1
(SD 2.3) mg/l for those on phenytoin (n=5)
and 56.8 (SD 10.0) mg/l for those on valproate
(n=5). In patients without postoperative sei-
zures these values were 11.7 (SD 6.7) (pheny-
toin, n=43) and 70 (SD 13) (valproate, n=43),
both significantly higher (p<0.05, t test). For
the total sample, excluding patients with a
change in medication, the steady state concen-
trations of phenytoin and valproate were 10.9
(SD 6.6) mg/l (range 4–28) and 68 (SD 13)
mg/l (range 44–100) respectively.
DOSAGE REGIMEN CHANGES
The initial therapy regimen of tablets thrice
daily remained unchanged in 81 patients, 38 of
them receiving phenytoin, 43 of them taking
valproate. Significantly more patients on
phenytoin had to reduce their drug regimen to
twice daily because of toxic drug plasma
concentrations, seven out of 50 patients on
phenytoin compared with no patients out of 50
on valproate (p=0.012, Fisher’s exact test). In
five patients receiving phenytoin and in seven
patients receiving valproate dosages had to be
increased after seizures.
One patient in the phenytoin group and two
in the valproate group experienced a single sei-
zure (with seizure freeedom after change of
dosage). The other 11 patients had multiple
seizures despite increased dosages. Subthera-
peutic dosages were in themselves no reason to
increase the dosage, whereas toxic dosages
were.
ADVERSE EFFECTS
Seven patients had to stop treatment because
of drug related side eVects, five patients in the
phenytoin group versus two in the valproate
group (not significant). Four patients treated
with phenytoin showed a hypersensitivity skin
reaction, occurring between 6 days and 4 weeks
after the start of treatment. After cessation of
the therapy recovery of the patients was
without sequelae within 1–2 weeks. In both
study groups patients had transient gastro-
intestinal complaints. In one patient treated
with phenytoin the nausea was persistent
despite treatment with several antiemetics, and
caused withdrawal from the trial. Also in both
groups equal numbers of liver function distur-
bances were found (total number of patients
six). In one patient treated with valproate there
was a marked rise in liver enzymes which
necessitated withdrawal from the trial. A
contributing factor could have been the
pre-existent minor disturbance of liver function
associated with the use of amiodarone. In all
patients liver enzymes returned to normal
values, without lasting consequences to the
patients. In one patient receiving valproate a
thrombopenia necessitated discontinuation of
treatment. Other known adverse eVects of the
Table 2 Attrition by medicine group and stratum
Phenytoin Valproate
Tumour Other Tumour Other
Completed trial 13 16 16 15
Died in week 1 1 0 1 0
2–6 2 1 1 1
7–12 2 0 1 0
13–26 3 0 0 4
27–52 4 0 2 0
Intercurrent illness 2 1 3 0
Adverse drug reaction 1 4 2 0
Needed concomitant medication 0 0 2 0
Withdrew informed consent 0 0 0 1
Lost to follow up 0 0 0 1
Table 3 Cases with seizures
Phenytoin Valproate Total
Preoperative 11 12 23
Simple partial 2 2 4
Generalised 9 9 18
Simple partial and generalised 0 1 1
Postoperative 7 (2) 7 (3) 14 (5)
Simple partial 3 (1) 2 (1) 5 (2)
Generalised 2 (1) 4 (2) 6 (3)
Simple partial and generalised 2 (0) 1 (0) 3 (0)
Pathology associated with postoperative seizures:
Malignant glioma 2 (1) 3 (0) 5 (1)
Metastasis 2 (1) 0 2 (1)
Low grade glioma 1 (0) 1 (1) 2 (1)
Meningioma 0 1 (1) 1 (1)
Neurocytoma 1 (0) 0 1 (0)
Cavernoma 0 1 (1) 1 (1)
Traumatic head injury 1 (0) 0 1 (0)
Aneurysm ant comm artery 0 1 (0) 1 (0)
The number of patients with postoperative seizures who also had preoperative seizures are shown
in parentheses.
Time (after operation) of first seizure.
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anticonvulsant drugs—for example, weight
gain with valproate and anaemia with
phenytoin—were minor and did not necessitate
cessation of trial medication.
NEUROPSYCHOLOGICAL TESTS AND QUALITY OF
LIFE
In a preliminary analysis, patients who were
available for psychological assessment after 3
months but not after 12 months (n=11) were
compared with patients who were assessed on
all three occasions (n=55). The first had a
higher mean age (p=0.03, t test) and scored on
average lower on immediate recall (p=0.007)
and word fluency (p=0.009) on the first assess-
ment; their rating of general wellbeing was also
lower (p=0.050) but other diVerences on qual-
ity of life measures were not significant.
In patients with complete data, the analysis
of neuropsychological test results disclosed no
significant diVerences between the phenytoin
and valproate groups. As table 4 shows, the
averages generally favoured the valproate
group, but the diVerences failed to reach
significance because the SDs were large.
Moreover, the interpretation of the learning
test results is complicated by significant group
by stratum interactions on all three measures,
immediate recall (p=0.006), delayed recall
(p=0.015) and recognition (p=0.005). In the
phenytoin group tumour patients tended to
score higher than other patients, but in the val-
proate group lower. For quality of life,
valproate patients tended to rate themselves as
less vigorous and more tired and tense than
phenytoin patients, especially at the 6 month
visit (table 5). However, the only significant
eVect was a quadratic group by visit interaction
on the POMS tension scale (p=0.008).
Discussion
Despite the frequent occurrence of seizures
after a craniotomy the routine use of anticon-
vulsant drugs as prophylaxis is controversial.
Anticonvulsant prophylaxis for the prevention
of seizures is recommended in general if the
risk of seizures exceeds 10%-15%, which is the
anticipated incidence of serious adverse drug
eVects.1 Prophylaxis is also advised when a sin-
gle seizure may have disastrous consequences
or when seizures are a major impediment to a
patient’s return to normal activity.
The choice of anticonvulsant prophylaxis
should be determined on one hand by the risks
and consequences of seizures during the
immediate postoperative period and during the
later course, and on the other hand by the eY-
cacy and tolerability of each anticonvulsant
drug. Furthermore, it should still be deter-
mined when to start and withdraw prophylactic
medication and what dosages should be
prescribed.
In this study, a randomised clinical trial
evaluating the clinical impact of two widely
used anticonvulsants as prophylaxis after crani-
otomy, we found no significant diVerences in
eYcacy and tolerability between the two treat-
ment groups: both in the phenytoin group and
the sodium valproate group the same number
of patients had seizures. In both groups the sei-
zures also had the same severity impact on
patients.
Our data are comparable with the data from
the double blind randomised trial carried out
by North et al44 who had a similar study popu-
lation and follow up of 1 year. In 281
postcraniotomy patients they compared 100
mg phenytoin thrice daily with placebo. Pheny-
toin significantly reduced seizure incidence
Table 4 Neuropsychological test results
3 Months 6 Months 12 Months
Phenytoin Valproate Phenytoin Valproate Phenytoin Valproate
M SD M SD M SD M SD M SD M SD
Word learning, immediate recall 34.7 13.8 37.8 11.0 39.0 15.7 41.9 10.9 40.6 17.2 47.3 12.6
Word learning, delayed recall 6.5 4.0 7.3 3.3 8.0 4.1 8.1 3.1 7.9 4.4 9.3 3.7
Word learning, recognition 27.1 3.4 27.8 1.7 27.1 3.0 28.1 2.5 27.3 3.8 28.7 2.7
Word fluency 32.2 13.2 36.4 12.2 35.4 13.5 37.2 10.7 36.9 13.2 37.1 12.7
Auditory reaction time (ms) 347 247 328 189 320 170 252 72 323 282 268 94
Binary choice (ms) 660 446 580 219 647 516 548 230 570 241 579 248
Visual search (s) 23.0 18.1 20.0 15.7 20.1 14.8 21.3 21.0 19.9 13.9 19.9 21.2
The data are derived from 55 patients (27 with phenytoin, 28 with valproate) whose assessment was complete.
Table 5 Quality of life measures
3 Months 6 Months 12 Months
Phenytoin Valproate Phenytoin Valproate Phenytoin Valproate
M SD M SD M SD M SD M SD M SD
POMS Depression 4.8 6.5 4.8 6.2 3.6 5.6 4.2 4.8 5.5 7.3 4.5 5.3
Tension 5.7 5.9 7.6 5.9 3.4 3.6 8.0 6.1 4.6 4.7 6.9 5.4
Vigour 11.3 4.8 10.6 4.0 13.3 3.8 10.0 4.7 12.1 4.0 10.2 4.4
Anxiety 5.2 4.9 4.3 5.1 3.7 4.2 4.2 5.1 5.3 5.3 4.8 4.7
Fatigue 5.6 5.7 5.4 5.0 3.2 2.6 5.9 4.9 4.5 4.1 5.6 5.0
Fatigue severity scale 33.8 16.6 37.6 13.3 29.6 11.7 37.2 13.0 33.4 13.4 3.7 15.9
Physical complaints 10.0 2.3 10.4 2.5 9.5 1.3 10.0 1.8 10.0 2.0 9.9 2.3
ADL dependency 8.2 1.8 8.9 3.4 7.3 1.5 8.0 2.5 7.1 1.3 7.7 2.3
Cognitive complaints 9.2 4.3 8.3 3.0 7.5 2.9 7.9 2.1 8.3 3.2 8.1 2.7
Impediment of daily functioning 2.5 1.0 2.4 1.1 2.1 0.9 2.0 0.9 2.3 1.0 2.1 1.1
Satisfaction with health 3.3 1.0 3.1 1.0 3.3 0.9 3.7 0.8 3.3 0.9 3.6 0.7
General wellbeing 3.1 0.9 3.1 1.2 3.8 0.9 3.7 1.0 3.6 0.9 3.8 0.8
The data are derived from 55 patients (27 with phenyroin, 28 with valproate) whose assessment was complete. ADL=Activities of daily living.
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(18 v 26 patients=12.9% v 18.4%) with highest
protection between days 7 and 72. The
incidence in their treatment group compares
well with the 14% seizure incidence we found
in both our study groups. In another ran-
domised trial,45 Foy et al compared phenytoin
or carbamazepine treatment with placebo for a
period of 6 or 24 months and found a
reduction of almost 10% in postoperative
seizures in the anticonvulsant groups. The dif-
ferences were not statistically significant, but
confidence limits were relatively wide. Because
no formulation of carbamazepine for intra-
venous use exists, this limits its use to patients
who are able to swallow and have reliable
gastrointestinal absorption. A diVerence with
our trial set up was the absence of regular drug
monitoring in their patients. In the 217 patients
(80%) in whom some concentrations were
monitored, concentrations of carbamazepine
usually were within the therapeutic range,
but—as in our study—a significant proportion
of phenytoin concentrations were below the
therapeutic range.
Our standard treatment regimen of 100 mg
phenytoin or 500 mg valproate three times
daily resulted in average blood concentrations
of 11.7 mg/l and 57 mg/l respectively in
patients without seizures (most patients); the
patients who experienced seizures had signifi-
cant lower blood concentrations. North et al2 44
also stress the importance of achieving thera-
peutic anticonvulsant concentrations. In their
trial, seven of the nine patients experiencing
generalised convulsions had subtherapeutic
drug concentrations. By contrast with our
findings, in which most patients irrespective of
seizure type had serum drug concentrations
below the regular therapeutic ranges, North et
al found a therapeutic concentration in seven
of nine patients with focal seizures. Because
both phenytoin and valproate are eVective in
preventing partial as well as generalised
tonic-clonic seizures,45 these diVerences in pro-
tection between these seizure types cannot be
easily explained.
Seizures in the immediate postoperative
period are correlated with the preoperative
lesion, the site of the lesion, postoperative
lesions, and subtherapeutic drug
concentration.20 46 We started treatment di-
rectly postoperatively when patients arrived at
the recovery room. Six patients experienced
their first seizure during the first postoperative
week, four had a first seizure already at the day
of the operation. In one patient the seizure was
associated with a postoperative haemorrhage.
In a placebo controlled randomised trial on
phenytoin Lee et al19 studied immediate and
early seizures in 374 patients. During the first 3
days, 11 patients (2.9%) developed seizures:
two in the phenytoin group and nine in the
placebo group; this diVerence was not signifi-
cant. Because 80% of the immediate seizures
occurred within 20 minutes after surgery they
recommended anticonvulsant drugs to be
given at least 20 minutes before completion of
wound closure. The advised therapeutic load-
ing dose for phenytoin varies between 7–10
mg/kg.47 48 For sodium valproate a schedule of
an intravenous 10 mg/kg bolus and 0.6 mg/kg/
hour sodium valproate is advised.49 Because
these anticonvulsant drugs need about 1 week
to reach a steady state drug plasma concentra-
tion, an even better option could be to start 1
week preoperatively, whenever possible, as was
advised by North et al.44
In our study, nine (64%) of the 14 patients
who experienced seizures had their first seizure
within 3 months after the operation. Of the 76
patients at risk at 3 months, five (7%) had their
seizure presentation within 6 months. These
findings are in line with the data from North et
al,44 in which three quarters of all seizures
occurred within 3 months.With a longer follow
up, the incidence in postoperative seizures
increases depending on the underlying pathol-
ogy: in cerebral abscess, first year incidence was
30%, rising to 72% after a median follow up of
11 years.50 Although some authors advocate
prophylaxis during one to several years,51 in the
long term, the benefits of seizure prevention
may not outweigh the risks of chronic anticon-
vulsant use. Our study supports the idea of
stopping prophylaxis after a 6 month period.
Further elucidation on this matter should be
obtained by a prospective study.
For toxicity and adverse eVects, in our study
more patients had to stop treatment due to
toxicity in the phenytoin group than in the val-
proate group (five phenytoin v two valproate).
The 8% incidence of hypersensitive skin
reactions associated with phenytoin use we
found is well comparable with the literature.52
Other known adverse eVects of both anticon-
vulsant drugs—for example, gastrointestinal
complaints, liver function disturbances, anae-
mia (phenytoin), and weight gain (valproate)—
were comparable with data reported in the
literature21 53 and were in most cases of minor
impact. Only in two patients (one in each
group) did it necessitate cessation of trial
medication.
With respect to the psychological evaluation,
patients with valproate showed a slight but
consistent advantage on cognitive measures,
whereas they tended to complain more of ten-
sion and fatigue. Whether larger group sizes
would have led to significant diVerences is
doubtful. It must be taken into account that the
patients had varied and often severe brain dis-
ease, and it is unlikely that the severity of the
cognitive eVects was entirely equated by the
randomisation procedure. In this respect an
increase in group sizes might well lead to
smaller diVerences. At any rate the diVerential
eVect of phenytoin and valproate on cognition
and quality of life seems negligible in compari-
son with the impact of disease and its
treatment.
In conclusion, we compared two regularly
used anticonvulsant drugs with both oral and
intravenous formulation at standard dosages.
No diVerence in either eYcacy or impact on
cognitive functioning and quality of life was
found between the two drugs. In favour of val-
proate was the lower number of patients show-
ing toxic serum drug concentrations. Both
drugs can be recommended for the use of
postoperative prophylaxis. For protection of
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immediate postoperative seizures it is advised
to start treatment 1 week before surgery, or if
that is not possible to start treatment with a
loading dose at least 20 minutes before wound
closure.
A timely detection and adjustment of
subtherapeutic concentrations is important;
this requires frequent monitoring of blood
concentrations, starting in the first postopera-
tive week. The anticonvulsant prophylaxis can
be stopped after 6 months.
Part of this study was presented at the 11th International Con-
gress of Neurological Surgery, held 4–11 July 1997 in Amster-
dam, The Netherlands. Drugs and an unrestricted educational
grant were supplied by Sanofi Winthrop v o f, Govert van
Wijnkade 48, 3144 EG Maassluis, The Netherlands.
1 Deutschman CS, Haines SJ. Anticonvulsant prophylaxis in
neurological surgery.Neurosurgery 1995;7:510–17.
2 North JB. Anticonvulsant prophylaxis in neurosurgery. Br J
Neurosurg 1989;3:425–7.
3 Foy PM, Copeland GP, Shaw MDM. The incidence of
postoperative seizures. Acta Neurochir 1981;55:253–64.
4 Bidzinski J, Koszewski W. The value of diVerent methods of
treatment of brain abscess in the CT era. Acta Neurochir
1990;105:117–20.
5 Legg NJ, Gupta PC, Scott DF. Epilepsy following cerebral
abscess. A clinical and EEG study of 70 patients. Brain
1973;96:259–68.
6 Northcroft GB, Wyke BD. Seizures following surgical treat-
ment of intracranial abscesses, a clinical and electroen-
cephalographic study. J Neurosurg 1956;14:249–63.
7 Jennett, B. Epilepsy after non-missile head injuries. 2nd ed.
London: Wm Heiman Medical Books, 1975.
8 Sundt TM jr, Kobayashi S, Fode NC, et al. Results and
complications of surgical management of 809 intracranial
aneurysms in 722 cases. Related and unrelated to grade of
patient, type of aneurysm, and timing of surgery. J
Neurosurg 1982;56:753–65.
9 Cabral RJ, King TT, Scott DF. Epilepsy after two diVerent
neurosurgical approaches to the treatment of ruptured
intracranial aneurysm. J Neurol Neurosurg Psychiatry 1976;
39:1052–6.
10 Forster DMC, Steiner L, Hakanson S. Arteriovenous
malformations of the brain; a long term clinical study. J
Neurosurg 1972;37:562–70.
11 Parkinson D, Bachers G. Arteriovenous malformations.
Summary of 100 consecutive supratentorial cases. J Neuro-
surg 1980;53:85–99.
12 Chozick BS, Reinert SE, Greenblatt SH. Incidence of
seizures after surgery for supratentorial meningeomas: a
modern analysis. J Neurosurg 1996;84:382–6.
13 Giombini S, Solero CL, Lasio G, et al. Immediate and late
outcome of operations for parasagittal and falx meningi-
omas. Surg Neurol 1984;21:427–35.
14 Ramamurthi B, Ravi R, Ramachandran V. Convulsions with
meningiomas: incidence and significance. Surg Neurol
1980;14:415–416
15 Moots PL,Maciunas RJ, Eisert DR, et al. The course of sei-
zure disorders in patients with malignant gliomas. Arch
Neurol 1995;52:717–24.
16 Boarini DJ, Beck DW, VanGilder JC. Postoperative prophy-
lactic anticonvulsant therapy in cerebral gliomas.Neurosur-
gery 1985;16:290–2.
17 Chan RC, Thompson GB. Morbidity, mortality and quality
of life following surgery for intracranial meningeomas. J
Neurosurg 1984;60:52–60.
18 Keranen T, Tapaninaho A, Hernesniemi J, et al. Late
epilepsy after aneurysm operations. Neurosurgery 1985;17:
897–900.
19 Lee ST, Lui TN, Chang CN, et al. Prophylactic anticonvul-
sants for prevention of immediate and early postcrani-
otomy seizures. Surg Neurol 1989;31:361–4.
20 Fukamachi A, Koizumi H, Nukui H. Immediate postopera-
tive seizures: incident and computed tomographic findings.
Surg Neurol 1985;24:671–6.
21 Dreifuss FE. Prevention as it pertains to epilepsy.Arch Neu-
rol 1995;52:363–06.
22 Price DJE. The advantages of sodium valproate in
neurosurgical practice. In: Legg NJ, ed. Clinical and
pharmacological aspects of sodium valproate in the treatment of
epilepsy. Kent: MCS Consultants;1976:44–49.
23 Gillham RA, Read CL, McKee PJW, et al. Cognitive
function in adult epileptic patients on long-term sodium
valproate. J Epilepsy 1991;4:205–10.
24 Devinsky 0. Cognitive and behavioral eVects of antiepileptic
drugs. Epilepsia 1995;36(suppl 2):46–65.
25 Craig I, Tallis R. Impact of valproate and phenytoin on cog-
nitive function in elderly patients: results of a single-blind
randomized comparative study. Epilepsia 1994;35:381–90.
26 Meador KJ, Loring DW,Moore EE, et al. Comparative cog-
nitive eVects of phenobarbital, phenytoin, and valproate in
healthy adults.Neurology 1995;45:1949–99.
27 Trimble MR, Thompson PJ. Anticonvulsant drugs, cogni-
tive function, and behavior. Epilepsia 1983;24(suppl 1):55–
63.
28 Forsythe I, Butler R, Berg I, et al. Cognitive impairment in
new cases of epilepsy randomly assigned to carbamazepine,
phenytoin, and sodium valproate. Dev Med Child Neurol
1991;33:524–35.
29 Helmstaedter C,Wagner G, Elger CE. DiVerential eVects of
first antiepileptic drug application on cognition in lesional
and non-lesional patients with epilepsy. Seizure 1993;2:
125–30.
30 Commission on classification and terminology of the inter-
national league against epilepsy. Proposal for revised classi-
fication of epilepsies and epileptic syndromes. Epilepsia
1989;30:389–99.
31 O’Donoghue MF, Duncan JS, Sander JWAS. The national
hospital seizure severity scale: a further development of the
Chalfont seizure severity scale. Epilepsia 1996;37:563–71.
32 Proost, JH, Meier, DKF. MW/Pharm, an integrated
software package for drug dose regimen calculation and
therapeutic drug monitoring. Comput Biol Med 1992;22:
155–63.
33 Moerland MC, Aldenkamp AP, Alpherts WCJ. Computer-
ized psychological testing in epilepsy. In: Maarse FJ,
Mulder LJM, Sjouw, WPB, et al, eds. Computers in
psychology: methods, instrumentation and psychodiagnostics.
Lisse: Swets and Zeitlinger, 1988:157–64.
34 Aldenkamp AP, Alpherts WCJ, Moerland MC, et al. Cogni-
tive side-eVects in patients with epilepsy. Epilepsia 1987;28:
507–14.
35 Alpherts WCJ, Aldenkamp AP, Moerland MC. An experi-
mental benzodiapine derivate. EVects on cognitive func-
tioning in patients with epilepsy. Prog Neuropsychopharma-
col Biol Psychtatry 1987;11:673–82.
36 Heslinga H, van den Burg W, Saan RJ. De nieuwe
15-woordentest A en B in een gezonde populatie (the new
15-words test in a healthy population) [unpublished doctoral
thesis]. Groningen, The Netherlands: University of Gron-
ingen, 1983.
37 Luteijn F, van der Ploeg FAE.Handleiding Groninger Intelli-
gentietest (Groningen intelligence test, manual). Lisse: Swets
and Zeitlinger, 1983.
38 Schmand B, Lindeboom J, van Harskamp F.De Nederlandse
Leestest voor Volwassenen. Handleiding (Dutch adult reading
test manual). Lisse: Swets and Zeitlinger 1992.
39 Nelson HE. The revised national adult reading test. Test
manual. Windsor: NFER-Nelson, 1991.
40 Wald FDM, Mellenbergh GJ. De verkorte versie van de
Nederlandse vertaling van de Profile of Mood States
(POMS). (The shortened version of the Dutch translation
of the POMS).Nederlands Tijdschrift voor Psychologie 1990;
45:86–90.
41 McNair DM, Lorr M, Droppleman LF. Edits manual for the
profile of mood states. San Diego: Educational and Industrial
Testing Service, 1971.
42 Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue
severity scale; application to patients with multiple sclerosis
and systemic lupus erythematosus Arch Neurol 1989;46:
1121–3.
43 Taphoorn MBJ, Klein Schiphorst A, et al. Cognitive
functions and quality of life in patients with lowgrade
gliomas:the impact of radiotherapy. Ann Neurol 1994;36:
48–54.
44 North JB, Penhall RK, Hanieh A, et al. Phenytoin and post-
operative epilepsy. A double-blind study. J Neurosurg 1983;
58:672–7.
45 Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med
1996;334:168–75.
46 Foy PM, Chadwick DW, Rajgopalan N, et al. Do prophylac-
tic anticonvulsant drugs alter the pattern of seizures after
craniotomy? J Neurol Neurosurg Psychiatry 1992;55:753–7.
47 Kvam DA, Loftus CM, Copeland B, et al. Seizures during
the immediate postoperative period.Neurosurgery 1983;12:
14–17.
48 Milde LN,McDonald MG. Therapeutic loading dose of the
phenytoin in anesthatized patients. J Neurosurg Anesthesiol
1989;1:73–5.
49 Tsolaki M, Yannacou-Peftoulidou M, Grammaticos P, et al.
Phenytoin plasma levels after intraoperative administra-
tion, for the prevention of post-craniotomy seizures. Acta
Neurochir (Wien) 1987;84:36–8.
50 Moore AJ, Bell BA, Berry DJ. Intravenous sodium valproate in
neurosurgery: repeat dose pharmacinetic study and safety assess-
ment in neurosurgical patients. Proceedings of the 4th
international symposium on sodium valproate and epilepsy.
1989:204–7.
51 Prior P, Legg NJ, Scott DF. Epilepsy following intracranial
surgery. In: Proceedings of the 5th European Symposion on Epi-
lepsy. London: International Bureau for Epilepsy; 1973:94–
98.
52 Krall RL. Prophylactic antiepileptic drugs after brain
surgery. Semin Neurol 1981;1:222–4.
53 Haruda F. Phenytoin hypersensitivity: 38 cases. Neurology
1979;29:1480–5.
54 Bruni J. Phenytoin. Toxicity. In: Levy RH, Mattson RH,
Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York:
Meldrum Raven Press; 1995:345–50.
480 Beenen, Lindeboom,Kasteleijn-Nolst Trenité, et al
